Company profile
Alkermes plc
small molecule / long-acting injectable neuroscience
ALKS · Nasdaq · Dublin, Ireland
Share price · ALKS
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
Aripiprazole lauroxil (Aristada Initio)(Aristada Initio) | Approved | Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule | Schizophrenia |
Aripiprazole lauroxil (Aristada)(Aristada) | Approved | Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule | Schizophrenia |
Olanzapine/samidorphan (Lybalvi)(Lybalvi) | Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist)Small molecule | Schizophrenia |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Unlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Unlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.